Letter from the Editor in Chief
- PMID: 35949647
- PMCID: PMC9359422
- DOI: 10.19102/icrm.2022.130707
Letter from the Editor in Chief
Conflict of interest statement
Dr. Mansour reports the reception of research grants from Abbott Laboratories, Biosense Webster, Johnson & Johnson, Boston Scientific, Medtronic, Pfizer, Boehringer Ingelheim, and SentreHeart. He is also a consultant for Abbott Laboratories, Biosense Webster, Johnson & Johnson, Boston Scientific, Janssen, Medtronic, Phillips, Novartis, and SentreHeart and reports an equity relationship with EPS Solutions. All aforementioned relationships are in the area of atrial fibrillation; Dr. Mansour additionally reports an equity relationship in the area of ventricular fibrillation with NewPace Ltd.
Similar articles
-
Letter to the Editor Regarding: Editor-in-Chief Letter "Optimism versus Pessimism: The Choice Is Yours".World Neurosurg. 2021 Apr;148:234. doi: 10.1016/j.wneu.2021.01.087. World Neurosurg. 2021. PMID: 33770841 No abstract available.
-
Letter from the New Editor-in-Chief.Life (Basel). 2014 Jan 8;4(1):1-3. doi: 10.3390/life4010001. Life (Basel). 2014. PMID: 25370026 Free PMC article.
-
November 2016 Letter to the Editor-in-Chief.J Orthop Sports Phys Ther. 2016 Nov;46(11):1012-1014. doi: 10.2519/jospt.2016.0203. J Orthop Sports Phys Ther. 2016. PMID: 27802798
-
January 2020 Letter to the Editor-in-Chief.J Orthop Sports Phys Ther. 2020 Jan;50(1):47-48. doi: 10.2519/jospt.2020.0201. J Orthop Sports Phys Ther. 2020. PMID: 31892289
-
September 2016 Letter to the Editor-in-Chief.J Orthop Sports Phys Ther. 2016 Sep;46(9):811-2. doi: 10.2519/jospt.2016.0202. J Orthop Sports Phys Ther. 2016. PMID: 27581182
References
Publication types
LinkOut - more resources
Full Text Sources